SCHEMBL6319785

SCHEMBL6319785

COC(C(=O)c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ALDH1A1 P00352 5/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP3A4 P08684 1/20 0.42
ALPG P10696 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11288937 0.91 ALDH1A1 (0.54) ALDH1A1GAALMNASMN1; SMN2CYP3A4
SCHEMBL6201112 0.91 ALDH1A1 (0.54) ALDH1A1GAALMNASMN1; SMN2CYP3A4
SCHEMBL6203941 0.83 NPSR1 (0.54) CES2CES1ALDH1A1GAALMNA
SCHEMBL6202201 0.82 CES2 (0.41) CES2CES1ALDH1A1GAALMNA
SCHEMBL6203176 0.81 MEN1 (0.51) CES2CES1ALDH1A1CYP3A4MEN1
SCHEMBL24327729 0.81 KDM4E (0.46) ALDH1A1GAALMNACYP3A4MEN1
SCHEMBL2388602 0.81 KDM4E (0.46) ALDH1A1GAALMNACYP3A4MEN1
SCHEMBL19734679 0.79 AOC3 (0.42) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL12742297 0.79 KMT2A (0.48) ALDH1A1GAALMNAMEN1KMT2A
SCHEMBL9999768 0.79 ALDH1A1 (0.51) ALDH1A1GAALMNASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050272036-A1 Ketones ASTRAZENECA AB (SE) 2005-12-08 US disclosed
US-20050107374-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-05-19 US disclosed
US-4304789-A Benzoin oxime fungicides SHELL OIL COMPANY (US) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107374-A1 Substituted heterocyclic compounds and methods of use ICOS, CD4, HLA-DRB1 CES2 4836/4885CES1 3141/4885ALDH1A1 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.